I use to compare PYC to IMU; but PYC has become its own multi-hydra beast, seemingly able to target any tissue/cellular type at will.
There was a gentleman at one of PYC’s local scientific fireside chats that queried about oncology targets - SF replied they are keen to pursue/have the team/capability - just not yet given priority list/funding constraint.
This may seem bold as we’re not even in clinic yet, but I think PYC will prove to be a game changer for precision medicine
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-79
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.015(13.6%) |
Mkt cap ! $536.5M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.5¢ | $366.7K | 3.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 664225 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 200000 | 1 |
View Market Depth
| Last trade - 12.14pm 26/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |